Company Overview of PaxVax, Inc.
PaxVax, Inc. operates as a biotechnology company that develops and commercializes vaccine candidates against various infectious diseases. Its products include PXVX0200, a single-dose oral vaccine against cholera; PXVX0103, an oral adenoviral-based vaccine against avian influenza (H5N1) or bird flu; a single-dose oral vaccine candidate for protection against anthrax; Ad4-env Clade C, a HIV vaccine component that expresses an optimized HIV envelope protein derived from a Clade C HIV strain; Ad4-mGag, a HIV vaccine component that expresses an optimized HIV gag protein; a two-dose whole virus inactivated vaccine candidate that encompasses various strains of dengue fever; and Vivotif, a live typh...
900 Veterans Boulevard
Redwood City, CA 94063
Founded in 2006
Key Executives for PaxVax, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Executive Vice President
Chief Scientific Officer and Executive Vice President
Chief Legal Officer and Executive Vice President
Compensation as of Fiscal Year 2015.
PaxVax, Inc. Key Developments
PaxVax, Inc. Announces Executive Changes
May 11 15
PaxVax, Inc. announced that the Board of Directors has appointed Nima Farzan as Chief Executive Officer and President. In this role, he will assume overall responsibility for PaxVax, including management of all R&D, manufacturing and commercial operations globally. Kenneth Kelley, co-founder and former CEO, will continue to serve PaxVax as a Director on the Company’s Board of Directors and as an Advanced Leadership Initiative Fellow at Harvard University focused on related global health issues. Mr. Farzan previously served as President and Chief Operating Officer. He joined PaxVax in September 2011 from Novartis AG. Most recently, he was Vice President of Marketing for Novartis Vaccines USA, where he was responsible for marketing, market access, pricing and key account sales, and also helped launch multiple new vaccines.
PaxVax, Inc. Announces Global Expansion of Commercial Network for its Typhoid Vaccine Vivotif
Apr 22 15
PaxVax, Inc. announced a series of new commercial partnerships and distribution agreements for its commercial typhoid vaccine Vivotif. These agreements will ensure the global availability of Vivotif across Europe and Australia and complement the company's growing direct sales and marketing capabilities in the United States. Vivotif is currently licensed for sale in 27 countries.Typhoid is one of the most commonly delivered travel vaccines, and these agreements will ensure the availability of Vivotif to people in the European and Australian markets who are travelling to regions of the world where typhoid is endemic. Vivotif is the only oral vaccine indicated for typhoid and look forward to working with new distribution partners to maintain a stable global supply of this effective vaccine.
PaxVax, Inc. Appoints Nima Farzan as President
Jan 21 15
PaxVax, Inc. announced the appointment of Nima Farzan as president and chief operating officer. Mr. Farzan, who has served as PaxVax COO for the past three years, will be responsible for the company’s global operations including the finance, production and commercial functions. The company also announced that Mr. Farzan has joined the company’s board of directors. Kenneth Kelley will continue to serve as the company’s chief executive officer and as a director.
Similar Private Companies By Industry
Recent Private Companies Transactions